121 related articles for article (PubMed ID: 27666635)
1. Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.
Demizu Y; Shibata N; Hattori T; Ohoka N; Motoi H; Misawa T; Shoda T; Naito M; Kurihara M
Bioorg Med Chem Lett; 2016 Oct; 26(20):4865-4869. PubMed ID: 27666635
[TBL] [Abstract][Full Text] [Related]
2.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
3. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
Shibata N; Miyamoto N; Nagai K; Shimokawa K; Sameshima T; Ohoka N; Hattori T; Imaeda Y; Nara H; Cho N; Naito M
Cancer Sci; 2017 Aug; 108(8):1657-1666. PubMed ID: 28556300
[TBL] [Abstract][Full Text] [Related]
4. Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules.
Okuhira K; Shoda T; Omura R; Ohoka N; Hattori T; Shibata N; Demizu Y; Sugihara R; Ichino A; Kawahara H; Itoh Y; Ishikawa M; Hashimoto Y; Kurihara M; Itoh S; Saito H; Naito M
Mol Pharmacol; 2017 Mar; 91(3):159-166. PubMed ID: 27965304
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemia.
Zhang X; Liu R; Huang B; Zhang X; Yu W; Bao C; Li J; Sun C
Oncol Lett; 2016 Oct; 12(4):2976-2981. PubMed ID: 27698886
[TBL] [Abstract][Full Text] [Related]
6. Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
Wang CG; Zhong L; Liu YL; Shi XJ; Shi LQ; Zeng L; Liu BZ
Integr Cancer Ther; 2017 Dec; 16(4):526-539. PubMed ID: 27698265
[TBL] [Abstract][Full Text] [Related]
7. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
8. α3β1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway.
Varzavand A; Hacker W; Ma D; Gibson-Corley K; Hawayek M; Tayh OJ; Brown JA; Henry MD; Stipp CS
Cancer Res; 2016 Nov; 76(22):6577-6587. PubMed ID: 27680681
[TBL] [Abstract][Full Text] [Related]
9. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug interactions with imatinib: An observational study.
Récoché I; Rousseau V; Bourrel R; Lapeyre-Mestre M; Chebane L; Despas F; Montastruc JL; Bondon-Guitton E
Medicine (Baltimore); 2016 Oct; 95(40):e5076. PubMed ID: 27749579
[TBL] [Abstract][Full Text] [Related]
11. Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.
Gaboriaud-Kolar N; Myrianthopoulos V; Vougogiannopoulou K; Gerolymatos P; Horne DA; Jove R; Mikros E; Nam S; Skaltsounis AL
J Nat Prod; 2016 Oct; 79(10):2464-2471. PubMed ID: 27726390
[TBL] [Abstract][Full Text] [Related]
12. Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
Al-Dewik NI; Morsi HM; Samara MM; Ghasoub RS; Gnanam CC; Bhaskaran SK; Nashwan AJ; Al-Jurf RM; Ismail MA; AlSharshani MM; AlSayab AA; Ben-Omran TI; Khatib RB; Yassin MA
Clin Med Insights Oncol; 2016; 10():95-104. PubMed ID: 27721664
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis.
Liu Y; Fang B; Jiang J; Wang P
J Cancer Res Ther; 2016 Oct; 12(Supplement):23-26. PubMed ID: 27721246
[TBL] [Abstract][Full Text] [Related]
14. The calcineurin protein phosphatase is dispensable for BCR-ABL-induced B-ALL maintenance, propagation and response to dasatinib.
Rocchetti F; Tran Quang C; Maragno AL; Nguyen J; Lasgi C; Ghysdael J
Leukemia; 2017 Jan; 31(1):248-251. PubMed ID: 27694923
[No Abstract] [Full Text] [Related]
15. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
Dieter SM; Heining C; Agaimy A; Huebschmann D; Bonekamp D; Hutter B; Ehrenberg KR; Fröhlich M; Schlesner M; Scholl C; Schlemmer HP; Wolf S; Mavratzas A; Jung CS; Gröschel S; von Kalle C; Eils R; Brors B; Penzel R; Kriegsmann M; Reuss DE; Schirmacher P; Stenzinger A; Federspil PA; Weichert W; Glimm H; Fröhling S
Ann Oncol; 2017 Jan; 28(1):142-148. PubMed ID: 27687311
[TBL] [Abstract][Full Text] [Related]
16. Oocyte cryopreservation for fertility preservation in women with cancer.
Domingo J; Garcia-Velasco JA
Curr Opin Endocrinol Diabetes Obes; 2016 Dec; 23(6):465-469. PubMed ID: 27685935
[TBL] [Abstract][Full Text] [Related]
17. Appendicitis caused by the metastasis of HER2-positive breast cancer.
Mori R; Futamura M; Morimitsu K; Yoshida K
Surg Case Rep; 2016 Dec; 2(1):104. PubMed ID: 27683008
[TBL] [Abstract][Full Text] [Related]
18. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
Rankin A; Klempner SJ; Erlich R; Sun JX; Grothey A; Fakih M; George TJ; Lee J; Ross JS; Stephens PJ; Miller VA; Ali SM; Schrock AB
Oncologist; 2016 Nov; 21(11):1306-1314. PubMed ID: 27682134
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation.
Shimokawa K; Shibata N; Sameshima T; Miyamoto N; Ujikawa O; Nara H; Ohoka N; Hattori T; Cho N; Naito M
ACS Med Chem Lett; 2017 Oct; 8(10):1042-1047. PubMed ID: 29057048
[TBL] [Abstract][Full Text] [Related]
20. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
